KRP-203, Sphingosine 1-Phosphate Receptor Type 1 Agonist, Ameliorates Atherosclerosis in LDL-R −/− Mice | Zendy

Francesco Potì | Zendy; F. Gualtieri | Zendy; Sandro Sacchi | Zendy; Gabriele Weißen-Plenz | Zendy; Georg Varga | Zendy; Martin F. Brodde | Zendy; Christian Weber | Zendy; Manuela Simoni | Zendy; Jerzy–Roch Nofer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

KRP-203, Sphingosine 1-Phosphate Receptor Type 1 Agonist, Ameliorates Atherosclerosis in LDL-R ^−/− Mice

Author(s) -

Francesco Potì,

F. Gualtieri,

Sandro Sacchi,

Gabriele Weißen-Plenz,

Georg Varga,

Martin F. Brodde,

Christian Weber,

Manuela Simoni,

Jerzy–Roch Nofer

Publication year - 2013

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.113.301347

Subject(s) - endocrinology , chemistry , stat protein , tumor necrosis factor alpha , agonist , receptor , medicine , cancer research , microbiology and biotechnology , biology , signal transduction , stat3

Sphingosine 1-phosphate (S1P) partly accounts for antiatherogenic properties of high-density lipoproteins. We previously demonstrated that FTY720, a synthetic S1P analog targeting all S1P receptors but S1P receptor type 2, inhibits murine atherosclerosis. Here, we addressed the identity of S1P receptor mediating atheroprotective effects of S1P.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research